Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $274.4 million.

  • Revolution Medicines' Non-Current Assets rose 49.26% to $274.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.4 million, marking a year-over-year increase of 49.26%. This contributed to the annual value of $230.7 million for FY2024, which is 26.45% up from last year.
  • As of Q3 2025, Revolution Medicines' Non-Current Assets stood at $274.4 million, which was up 8.42% from $253.1 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Non-Current Assets ranged from a high of $274.4 million in Q3 2025 and a low of $111.4 million during Q3 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $183.7 million (2024), whereas its average is $198.2 million.
  • Per our database at Business Quant, Revolution Medicines' Non-Current Assets dropped by 0.65% in 2021 and then spiked by 49.26% in 2025.
  • Over the past 5 years, Revolution Medicines' Non-Current Assets (Quarterly) stood at $148.2 million in 2021, then rose by 2.38% to $151.7 million in 2022, then increased by 20.22% to $182.4 million in 2023, then climbed by 26.45% to $230.7 million in 2024, then soared by 49.26% to $274.4 million in 2025.
  • Its last three reported values are $274.4 million in Q3 2025, $253.1 million for Q2 2025, and $230.8 million during Q1 2025.